Treace Medical Concepts annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Treace Medical Concepts Stock-Based Compensation Growth & History (TMCI)
Treace Medical Concepts's stock-based compensation was $33.8M for fiscal 2025.
View full Treace Medical Concepts company overviewTreace Medical Concepts annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $33.8M | $3.2M | +10.52% |
| 2024 | 2024-12-31 | $30.6M | $13.3M | +76.37% |
| 2023 | 2023-12-31 | $17.4M | $9.2M | +113.93% |
| 2022 | 2022-12-31 | $8.1M | $4.7M | +137.93% |
| 2021 | 2021-12-31 | $3.4M | $2.5M | +270.95% |
| 2020 | 2020-12-31 | $919,000 | $104,000 | +12.76% |
| 2019 | 2019-12-31 | $815,000 | — | — |
Treace Medical Concepts quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $6.5M | −$3.1M | −32.52% |
| Q1 2026 | 2026-03-31 | $8.0M | −$659,000 | −7.58% |
| Q4 2025 | 2025-12-31 | $7.6M | −$1.0M | −11.69% |
| Q3 2025 | 2025-09-30 | $8.0M | $98,000 | +1.24% |
| Q2 2025 | 2025-06-30 | $9.6M | $2.8M | +42.09% |
| Q1 2025 | 2025-03-31 | $8.7M | $1.3M | +17.35% |
| Q4 2024 | 2024-12-31 | $8.6M | $2.7M | +45.69% |
| Q3 2024 | 2024-09-30 | $7.9M | $2.7M | +52.16% |
| Q2 2024 | 2024-06-30 | $6.7M | $3.1M | +87.43% |
| Q1 2024 | 2024-03-31 | $7.4M | $4.7M | +175.19% |
| Q4 2023 | 2023-12-31 | $5.9M | $3.4M | +137.73% |
| Q3 2023 | 2023-09-30 | $5.2M | $2.9M | +128.82% |
| Q2 2023 | 2023-06-30 | $3.6M | $1.6M | +83.19% |
| Q1 2023 | 2023-03-31 | $2.7M | $1.3M | +91.06% |
| Q4 2022 | 2022-12-31 | $2.5M | $1.2M | +91.03% |
| Q3 2022 | 2022-09-30 | $2.3M | $1.4M | +170.44% |
| Q2 2022 | 2022-06-30 | $2.0M | $1.1M | +124.34% |
| Q1 2022 | 2022-03-31 | $1.4M | $1.0M | +250.50% |
| Q4 2021 | 2021-12-31 | $1.3M | $956,000 | +283.68% |
| Q3 2021 | 2021-09-30 | $839,000 | $714,000 | +571.20% |
| Q2 2021 | 2021-06-30 | $875,000 | $627,000 | +252.82% |
| Q1 2021 | 2021-03-31 | $402,000 | $193,000 | +92.34% |
| Q4 2020 | 2020-12-31 | $337,000 | — | — |
| Q3 2020 | 2020-09-30 | $125,000 | — | — |
| Q2 2020 | 2020-06-30 | $248,000 | — | — |
| Q1 2020 | 2020-03-31 | $209,000 | — | — |
Treace Medical Concepts stock-based compensation trends
Over the last five fiscal years, Treace Medical Concepts's stock-based compensation increased from $919,000 to $33.8M, a change of $32.9M. The latest reported quarter, Q2 2026, shows $6.5M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Treace Medical Concepts source filings ↗